The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s stock for more than a decade, The Times’ Ben Martin reports. Citadel, the $65B American investment firm, has built a net short position equating to 0.51 percent of GSK’s issued share capital, according to filings with the Financial Conduct Authority, the City regulator. It is the first time since late 2013 that an investor has amassed a short in GSK that is large enough to reach the 0.5 percent threshold requiring a public notification to the City authority.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Balanced Risk-Reward Outlook for GSK Amid Modest Growth and Market Challenges
- GSK initiated with an Equal Weight at Morgan Stanley
- GSK price target raised to 1,500 GBp from 1,440 GBp at JPMorgan
- Trump Trade: President advocates to close carried interest tax loophole
- GSK sued by Arizona AG for engaging in ‘deceptive’ practices